Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Xcel Energy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.76 (market cap $39.89B), while Xcel Energy Inc trades at $80.5 (market cap $49.98B). The key difference: Xcel Energy Inc is the larger of the two by market cap, and Xcel Energy Inc pays a 2.96% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | XEL | |
|---|---|---|
Market Cap | $39.89B | $49.98B |
Sector | Health | Utilities |
52-Week High | $491.22 | $83.91 |
52-Week Low | $278.09 | $68.33 |
Enterprise Value | $38.15B | $87.42B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
XEL trades at $80.06, up 1.32% today, with a bearish technical signal but strong analyst consensus. Recent earnings showed a Q1 2026 beat but two prior misses. The company maintains solid fundamentals with $14.67B revenue, 14.14% net margin, and a $60B capital plan driving growth. Dividend yield is 2.87% with a recent $0.59 payout declared.
Outlook is positive with Wall Street's $91.88 price target suggesting 15% upside, supported by data center demand and infrastructure investments. Risks include regulatory pushback on rate hikes and high debt levels. The stock presents a steady utility play with growth catalysts but requires monitoring of earnings consistency and capex execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
